SINGAPORE, Sept 12 (Bernama-GLOBE NEWSWIRE) -- Lightstone Ventures (LSV) today announced that MediSix Therapeutics Pte Ltd., an early-stage cell therapy company developing novel therapeutics to target T-cell leukemia and lymphoma, has signed an exclusive licensing agreement with the National University of Singapore (NUS).
Lightstone Singapore, L.P. and Professor Dario Campana from the Department of Pediatrics, NUS Yong Loo Lin School of Medicine founded MediSix in 2016 to develop novel Chimeric Antigen Receptor (CAR) T-cell immunotherapies. Through this licensing agreement, effective August 7, 2017, MediSix is licensing certain patent and technology rights from NUS. MediSix will further develop the underlying intellectual property (IP) for commercial applications.
http://mrem.bernama.com/viewsm.php?idm=30021
No comments:
Post a Comment